Granisetron HCl Injection Rx
Generic Name and Formulations:
Granisetron (as HCl) 1mg/mL (contains benzyl alcohol); 0.1mg/mL (preservative-free); IV inj.
Various generic manufacturers
Indications for Granisetron HCl Injection:
Prevention of nausea and vomiting associated with chemotherapy (including high-dose cisplatin). Prevention and treatment of post-op nausea and vomiting.
Adults and Children:
Chemotherapy: give as an undiluted IV injection over 30 seconds or as a diluted IV infusion over 5 minutes. <2 years: not recommended; ≥2 years: 10micrograms/kg starting within 30 minutes of initiating chemotherapy, only on the days chemotherapy is given. Post-op (adults): infuse 1mg undiluted IV over 30 seconds. For prevention, give before induction of anesthesia or immediately before reversal of anesthesia. Post-op (children): not recommended.
Abdominal surgery. May mask progressive ileus and/or gastric distention. Pre-existing arrhythmias or cardiac conduction disorders. Cardiac disease, concomitant cardio-toxic chemotherapy or electrolyte abnormalities: increased risk of QT prolongation. Pregnancy (Cat.B). Nursing mothers.
Caution with drugs that affect CYP450 or prolong the QT interval.
Selective 5-HT3 receptor antagonist.
Headache, asthenia, diarrhea, constipation; QT prolongation.
Formerly known under the brand name Kytril.
Sign Up for Free e-newsletters
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|